Cardiovalve Submits CE Approval Dossier Following TARGET Trial Success Cardiovalve has submitted a CE technical dossier for its transcatheter tricuspid valve replacement system, following promising TARGET study results.

Cardiovalve Submits CE Approval Dossier Following TARGET Trial Success #China #Hangzhou #Venus_Medtech #Cardiovalve #TARGET_Study

Cardiovalve Submits CE Application Following TARGET Study Success Venus Medtech announces that Cardiovalve has submitted the CE application for its transcatheter tricuspid valve replacement system after the successful TARGET study with 150 patients.

Cardiovalve Submits CE Application Following TARGET Study Success #China #Hangzhou #Venus_Medtech #Cardiovalve #TTVR

Cardiovalve Submits CE Technical File for Approval After Successful TARGET Study Completion Venus Medtech announces Cardiovalve has submitted a CE technical file for its transcatheter replacement system following positive TARGET trial results.

Cardiovalve Submits CE Technical File for Approval After Successful TARGET Study Completion #USA #London #Venus_Medtech #Cardiovalve #TTVR

Cardiovalve Achieves Key CE Submission After Successful TARGET Study Results Cardiovalve has submitted its CE technical file for the transcatheter tricuspid valve replacement device, achieving a significant milestone post-TARGET study.

Cardiovalve Achieves Key CE Submission After Successful TARGET Study Results #None #Venus_Medtech #Cardiovalve #TARGET_Study

Cardiovalve Advances in Heart Valve Technology with CE Submission After TARGET Study Success Cardiovalve has submitted its CE technical file for a new valve system after successful TARGET study results, marking a significant step in heart treatment technology.

Cardiovalve Advances in Heart Valve Technology with CE Submission After TARGET Study Success #China #Hangzhou #Venus_Medtech #Cardiovalve #TARGET_Study

Cardiovalve Completes Enrollment for TARGET Study Focused on Tricuspid Valve Replacement CE Approval Cardiovalve has successfully completed patient recruitment for its TARGET study, moving towards CE marking for its tricuspid valve replacement system, with a launch expected in 2027.

Cardiovalve Completes Enrollment for TARGET Study Focused on Tricuspid Valve Replacement CE Approval #China #Hangzhou #Venus_Medtech #Cardiovalve #TTVR

Cardiovalve Successfully Completes TARGET Study Patient Enrollment for CE Registration Cardiovalve has finalized patient recruitment for the TARGET study, crucial for its CE marking application. This opens the path for commercial launch in 2027.

Cardiovalve Successfully Completes TARGET Study Patient Enrollment for CE Registration #China #Hangzhou #Venus_Medtech #Cardiovalve #TTVR

Cardiovalve Reaches Key Milestone After Completing TARGET Study Enrollment for Tricuspid Valve Replacement Venus Medtech's Cardiovalve marks a crucial step forward by successfully finishing the TARGET study enrollment, allowing advancement toward CE approval for Tricuspid Valve Replacement.

Cardiovalve Reaches Key Milestone After Completing TARGET Study Enrollment for Tricuspid Valve Replacement #China #Hangzhou #Venus_Medtech #Cardiovalve #CE_Mark

Cardiovalve Completes Enrollment for CE Registration of TTVR System Venus Medtech's Cardiovalve has finished enrolling 150 patients for the TARGET study, pushing towards CE Mark approval for its TTVR system, with commercial launch slated for 2027.

Cardiovalve Completes Enrollment for CE Registration of TTVR System #China #Hangzhou #Venus_Medtech #Cardiovalve #TTVR_System

Completion of TARGET Study Enrollment Signals Cardiovalve's Path to CE Mark Approval Cardiovalve has concluded patient recruitment for its TARGET study, marking a significant step towards obtaining CE mark approval for its tricuspid valve replacement technology, aiming for a 2027 commercial launch.

Completion of TARGET Study Enrollment Signals Cardiovalve's Path to CE Mark Approval #China #Hangzhou #Venus_Medtech #Cardiovalve #TTVR

Venus Medtech Wins Major Patent Victory for Cardiovalve Against Edwards Lifesciences Venus Medtech secures a significant patent victory for Cardiovalve against Edwards Lifesciences, solidifying its position in heart therapies.

Venus Medtech Wins Major Patent Victory for Cardiovalve Against Edwards Lifesciences #China #Edwards_Lifesciences #Hangzhou #Venus_Medtech #Cardiovalve

Cardiovalve Secures Major Legal Win Against Edwards in Patent Dispute Venus Medtech’s Cardiovalve Ltd. has celebrated a pivotal legal victory against Edwards, reinforcing its patent rights in cardiac treatments. This judgment enhances Cardiovalve's competitive edge.

Cardiovalve Secures Major Legal Win Against Edwards in Patent Dispute #China #Edwards_Lifesciences #Hangzhou #Venus_Medtech #Cardiovalve

Venus Medtech's Cardiovalve Wins Major Patent Case Against Edwards Lifesciences Venus Medtech's subsidiary Cardiovalve achieves a significant patent victory against Edwards Lifesciences, reinforcing its innovative cardiac technologies and market position.

Venus Medtech's Cardiovalve Wins Major Patent Case Against Edwards Lifesciences #China #Edwards_Lifesciences #Hangzhou #Venus_Medtech #Cardiovalve

Cardiovalve Secures Major Legal Victory Against Edwards in Patent Dispute Cardiovalve, a subsidiary of Venus Medtech, clinched a significant legal victory against Edwards Lifesciences, solidifying its patent rights in transcatheter heart valve technologies.

Cardiovalve Secures Major Legal Victory Against Edwards in Patent Dispute #China #Hangzhou #Venus_Medtech #Cardiovalve #Edwards

Venus Medtech Secures Important Patent Victory for Cardiovalve Against Edwards Lifesciences Venus Medtech announced a legal victory for its subsidiary Cardiovalve against Edwards Lifesciences, affirming Cardiovalve's patent in a critical case.

Venus Medtech Secures Important Patent Victory for Cardiovalve Against Edwards Lifesciences #China #Edwards_Lifesciences #Hangzhou #Venus_Medtech #Cardiovalve

Venus MedTech Reports 2024 Financial Results: Profitability Driven by Global Expansion and Innovation Venus MedTech has reported its robust annual results for 2024, highlighting significant profitability thanks to global expansion and inventive strategies that enhanced operational efficiency and growth.

Venus MedTech Reports 2024 Financial Results: Profitability Driven by Global Expansion and Innovation #TAVR #Venus_Medtech #Cardiovalve